{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:07:55Z","timestamp":1761894475715,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":2931,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.bbmt.2006.11.011","type":"journal-article","created":{"date-parts":[[2007,2,3]],"date-time":"2007-02-03T02:46:00Z","timestamp":1170470760000},"page":"423-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"13","author":[{"given":"George E.","family":"Georges","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Maris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed L.","family":"Sorror","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith A.","family":"Shizuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thoralf","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward D.","family":"Agura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"McSweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Chauncey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Mielcarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry E.","family":"Storer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2006.11.011_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.11.011_bib2","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.11.011_bib3","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.11.011_bib4","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/sj.leu.2402613","article-title":"Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma","volume":"16","author":"Moreau","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2006.11.011_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2141.2002.03231.x","article-title":"Predicting long-term (\u2265 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants","volume":"116","author":"Tricot","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.bmt.1704757","article-title":"Cure of myeloma: hype or reality?","volume":"35","author":"Fassas","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.011_bib7","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib8","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.bmt.1701208","article-title":"Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?","volume":"21","author":"Mehta","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.011_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u201398 at European Group for Blood and Marrow Transplantation centres","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/sj.bmt.1704868","article-title":"Outcome of unrelated transplants in patients with multiple myeloma","volume":"35","author":"Ballen","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.011_bib11","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib12","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood-2003-02-0482","article-title":"HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies","volume":"102","author":"Maris","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2002-08-2628","article-title":"Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation","volume":"102","author":"Mielcarek","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib14","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood-2004-03-0804","article-title":"Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors","volume":"104","author":"Diaconescu","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood-2004-02-0545","article-title":"Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities","volume":"104","author":"Sorror","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib17","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V99.3.1071","article-title":"Limiting transplantation-related mortality following unrelated donor stem cell transplantion by using a nonmyeloablative conditioning regimen","volume":"99","author":"Chakraverty","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.2002.20.5.1295","article-title":"Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning","volume":"20","author":"Badros","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","article-title":"Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma","volume":"30","author":"Giralt","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.011_bib22","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib24","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","article-title":"Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2141.2003.04299.x","article-title":"Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning","volume":"121","author":"Einsele","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0301-472X(02)01010-X","article-title":"Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced-intensity conditioning","volume":"31","author":"Lee","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib27","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1365-2141.2003.04714.x","article-title":"The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma","volume":"123","author":"Shaw","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib28","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"Niederwieser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","article-title":"Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity","volume":"9","author":"Peggs","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.011_bib30","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","article-title":"Relapse to previous autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma","volume":"10","author":"Kroger","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.011_bib31","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2005.12.030","article-title":"Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing","volume":"12","author":"Maris","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.011_bib33","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1182\/blood.V92.10.3515","article-title":"Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient","volume":"92","author":"Petersdorf","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00000421-199808000-00019","article-title":"A randomized trial of mobilization of peripheral blood stem cells with cyclophosphamide, etoposide, and granulocyte colony-stimulating factor with or without cisplatin in patients with malignant lymphoma receiving high-dose chemotherapy","volume":"21","author":"Weaver","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib35","series-title":"Thomas\u2019 Hematopoietic Cell Transplantation","first-page":"635","article-title":"Graft-vs-host disease","author":"Sullivan","year":"2004"},{"key":"10.1016\/j.bbmt.2006.11.011_bib36","series-title":"Thomas\u2019 Hematopoietic Cell Transplantation","first-page":"234","article-title":"Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation","author":"Bryant","year":"2004"},{"key":"10.1016\/j.bbmt.2006.11.011_bib37","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib38","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib39","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib40","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2005.08.136","article-title":"Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning","volume":"23","author":"Baron","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib41","first-page":"7","article-title":"Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy","volume":"16","author":"Tricot","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.011_bib42","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.11.011_bib43","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.11.011_bib44","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib45","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2005-11-4449","article-title":"Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma","volume":"107","author":"van de Donk","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.011_bib46","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib47","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.11.011_bib48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.bmt.1701943","article-title":"Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma","volume":"24","author":"Rajkumar","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.011_bib49","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1365-2141.2002.03757.x","article-title":"Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma","volume":"118","author":"Fassas","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2006.11.011_bib50","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/1042819031000067567","article-title":"Predicting long-term survival in multiple myeloma patients following autotransplants","volume":"44","author":"Fassas","year":"2003","journal-title":"Leuk Lymphoma"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879106007658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879106007658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:29:03Z","timestamp":1761056943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879106007658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S1083879106007658"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.11.011","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}